Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 mars 2007 08h00 HE | Source: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals Advances Difimicin Into Phase 3 Clinical Trial

SAN DIEGO, March 14, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today reported that the U.S. Food and Drug Administration has agreed with the recommendation of the...
27 févr. 2007 08h00 HE | Source: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals Regains North American Rights to Difimicin (Par-101/Opt-80)

SAN DIEGO, Feb. 27, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the company has regained North American rights to Difimicin (PAR-101/OPT-80) from Par...
21 févr. 2007 08h00 HE | Source: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option by Underwriters

SAN DIEGO, Feb. 21, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the underwriters of the company's recent initial public offering of common stock have...
09 févr. 2007 08h00 HE | Source: Optimer Pharmaceuticals, Inc.

Optimer Pharmaceuticals, Inc. Announces Pricing For Initial Public Offering

SAN DIEGO, Feb. 9, 2007 (PRIME NEWSWIRE) -- Optimer Pharmaceuticals, Inc. announced today the initial public offering of 7,000,000 shares of its common stock at a price of $7.00 per share. The common...